Get the Stockscreener App
3.105
11.69%
0.325
Armata Pharmaceuticals Inc stock is traded at $3.105, with a volume of 105.39K.
It is up +11.69% in the last 24 hours and down -29.43% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$2.78
Open:
$2.86
24h Volume:
105.39K
Relative Volume:
1.01
Market Cap:
$115.45M
Revenue:
$5.20M
Net Income/Loss:
$-282.61M
P/E Ratio:
-0.3999
EPS:
-7.764
Net Cash Flow:
$-24.47M
1W Performance:
-19.56%
1M Performance:
-29.43%
6M Performance:
-74.25%
1Y Performance:
-8.94%
1-Day Range:
$2.83
$3.155
1-Week Range:
$2.745
$3.9525
52-Week Range:
$2.745
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
3.105 | 115.45M | 5.20M | -282.61M | -24.47M | -7.764 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Form 8K Armata Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com South Africa
Deborah Birx is scheduled to present for Armata on Sept. 16 - Stock Titan
Armata Pharmaceuticals Stock Price Forecast. Should You Buy ARMP? - StockInvest.us
Armata Pharmaceuticals (ARMP) Advances Phage Therapy Research Am - GuruFocus
Armata Pharmaceuticals publishes phage research findings By Investing.com - Investing.com Australia
Armata Pharmaceuticals publishes phage research findings - Investing.com
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials - PR Newswire
Armata Pharmaceuticals Inc. (ARMP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
JonesTrading Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Armata (ARMP) Results Check: EPS Falls Short of Its Estimate in the Latest Session; Price Reaction - vinanet.vn
Armata (ARMP) Today: Finishes 12.82% Lower at $4.42; Chart View: Price Remains Between $4.20 Support and $4.64 Resistance in the Available RecordLow Volatility Picks - vinanet.vn
Armata (ARMP) Earnings Report: EPS Falls Short of Its Estimate on the Day; Investor Response: The Market Price Advances 11.18%Earnings Preview - vinanet.vn
Madison Asset Management LLC Buys New Position in Armata Pharmaceuticals, Inc. $ARMP - MarketBeat
Armata (ARMP) Earnings Review: The EPS Result Is Below Expectation under the Current Snapshot; Post-Report Move: Shares Rise 1.79%Return On Equity - vinanet.vn
ARMP Q1 2026 Earnings: Severe EPS Miss Deepens as Clinical-Stage Costs Pressure Results - vinanet.vn
HC Wainwright Forecasts Armata Pharmaceuticals Q3 Earnings - MarketBeat
Armata Pharmaceuticals, Inc. Revenue Breakdown – AMEX:ARMP - TradingView
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Armata Pharma earnings beat by $0.17, revenue topped estimates - Investing.com
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
Is Armata Pharmaceuticals Inc (ARMP) Facing Challenges After Q2 - GuruFocus
Armata Pharmaceuticals, Inc. 2026: Revenue $2.51M, Net income $74.14M, EPS ($0.27) — 10-Q Summary - TradingView
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update - PR Newswire
Armata Pharmaceuticals posts $74.1M net income in Q2 2026 on non-cash gain - scanx.trade
ARMP Q1 2026 Earnings: Deep EPS Miss and No Revenue Spotlight Clinical-Stage Cash BurnGuidance Revision Trend - Vinanet
[ARMP] Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-than-Expected Net LossQuarterly Financial Update - vinanet.vn
Armata Pharmaceuticals (ARMP) Dips 2% as Shares Approach Key Support at $4.37Breakout Confirmation - vinanet.vn
Armata Pharmaceuticals (ARMP) Slips 5% as Biotech Volatility Weighs on Clinical-Stage StockIntraday Trade Ideas - vinanet.vn
Armata Pharmaceuticals (ARMP) Slips 5% as Biotech Volatility Weighs on Clinical-Stage StockTrend Reversal Picks - dars.gov.et
Armata Pharmaceuticals, Inc. Actuals & Estimates (AMEX:ARMP) - TradingView
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Net Loss Wide of Estimates, Cash Burn Remains a Focus - vinanet.vn
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Wider-than-Expected Loss Intensifies Investor CautionPost-Announcement Reaction - dars.gov.et
Armata Pharmaceuticals Inc - TradingKey
Armata Pharmaceuticals Inc (ARMP) Cash Flow - TradingKey
TradingKey - TradingKey
ARMP|Armata Pharmaceuticals Inc|Price:5.150|Chg%:+0.490 - TradingKey
Armata Pharmaceuticals Inc (ARMP) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
ARMP|Armata Pharmaceuticals Inc|Price:4.650|Chg%:-0.570 - TradingKey
Armata Pharmaceuticals Inc (ARMP) Institutional Confidence - TradingKey
Daniel B. Gilmer Net Worth (2026) - GuruFocus
Armata Pharmaceuticals, Inc. (ARMP) stock price, news, quote and history - Yahoo Finance Singapore
Armata Pharmaceuticals, Inc. (ARMP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP) - The Globe and Mail
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Yahoo! Finance Canada
Armata Pharmaceuticals (ARMP) Advances Towards Phase 3 Study for AP-SA02 - GuruFocus
Armata Pharmaceuticals (ARMP) Advances Towards Phase 3 Study for AP-SA02 - GuruFocus
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - Yahoo Finance
Armata (ARMP) Names David House as New CFO to Lead Financial Str - GuruFocus
Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug Treatment - Moomoo
Armata (ARMP) Names David House as New CFO to Lead Financial Str - GuruFocus
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):